Targeting the PVR axis using CAR T cell therapy and combinations
AssigneeRoswell Park Cancer Institute
InventorsAJ Robert McGray, Jessie Chiello
Life of this patent
Estimating the term…
Abstract
Provided is a method of treating cancer in an individual by administering to the individual modified cells that express a chimeric antigen receptor (CAR) that contain a TIGIT extracellular domain that can bind to poliovirus receptor (PVR), a CD28 segment, and a CD3ζ segment. The modified cells may co-express and secrete a Bi-specific T cell engager (BiTE). The BiTE includes a segment that can specifically bind to human Folate Receptor alpha (FRα) and a segment that that can specifically bind to a human CD3□ segment. Modified cells that express the CAR, and may also express and secrete the BiTE, and polynucleotides encoding the CAR and the BiTE, are also provided.
Claims11
A method of treating ovarian cancer in an individual by administering to the individual modified T cells, wherein the modified T cells are modified i) to express a chimeric antigen receptor (CAR), the CAR comprising a T cell immunoreceptor with immunoglobulin and tyrosine-based inhibitory motif (TIGIT) extracellular domain that can bind to poliovirus receptor (PVR), a CD28 segment, and a CD3ζ segment;
- and ii) to express and secrete a Bi-specific T cell engager (BiTE), wherein the BiTE includes a segment that can specifically bind to human Folate Receptor alpha (FRα) and a segment that that can specifically bind to a human CD3ε segment.
Dependencies are inferred from the claim text.